Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Acquisitions & Divestments (2017 - 2025)

Coherus Oncology's Change in Acquisitions & Divestments history spans 8 years, with the latest figure at $19.8 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 696.3% year-over-year to $19.8 million; the TTM value through Dec 2025 reached $22.3 million, up 156.68%, while the annual FY2025 figure was $21.5 million, 147.03% up from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $19.8 million at Coherus Oncology, up from $2.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $131.1 million in Q4 2023 and bottomed at -$51.5 million in Q3 2023.
  • The 4-year median for Change in Acquisitions & Divestments is $19.8 million (2025), against an average of $28.6 million.
  • The largest annual shift saw Change in Acquisitions & Divestments plummeted 98.1% in 2024 before it skyrocketed 696.3% in 2025.
  • A 4-year view of Change in Acquisitions & Divestments shows it stood at $37.0 million in 2021, then soared by 254.34% to $131.1 million in 2023, then tumbled by 98.1% to $2.5 million in 2024, then surged by 696.3% to $19.8 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Change in Acquisitions & Divestments are $19.8 million (Q4 2025), $2.5 million (Q4 2024), and $6.2 million (Q1 2024).